Hong Liag Wu
Financieel Directeur/CFO bij Jumpcan Pharmaceutical Co. Ltd.
Profiel
Hong Liag Wu is currently working as the Chief Financial Officer & Secretary at Jumpcan Pharmaceutical Co. Ltd.
Previously, Wu worked as the Chief Financial Officer & Board Secretary at Hubei Jumpcan Pharmaceutical Co., Ltd.
Actieve functies van Hong Liag Wu
| Bedrijven | Functie | Begin |
|---|---|---|
Jumpcan Pharmaceutical Co. Ltd.
 Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the private company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Financieel Directeur/CFO | - |
Eerdere bekende functies van Hong Liag Wu
| Bedrijven | Functie | Einde |
|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Financieel Directeur/CFO | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Jumpcan Pharmaceutical Co. Ltd.
Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the private company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Health Technology |
